![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 09, 2018 1:08:12 PM
Previously, had:
mITT
placebo: 15/25 60.0%
brilacidin: 9/21 42.8%
PP
placebo: 12/20 60.0%
brilacidin: 7/19 36.8%
Now have:
mITT-cisplatin q. 3 wk
placebo: 10/14 71.4%
brilacidin: 3/12 25.0%
mITT-cisplatin q. 1 wk
placebo: 5/11 45.5%
brilacidin: 6/9 66.7%
PP-cisplatin q. 3 wk
placebo: 8/11 72.7%
brilacidin: 2/14 14.3%
PP-cisplatin q. 1 wk
placebo: 4/9 44.4%
brilacidin: 5/5 100.0%
Even smaller numbers, but shows statistical significance for prevention of SOM in subgroup getting cisplatin q. 3 weeks, but now more get SOM in subjgroup getting cisplatin q. 1 week...
Could be meaningless statistical noise, or perhaps brilacidin protects against the higher dose cisplatin, but not the lower dose cisplatin (spread out doses).
It seems that most people can't tolerate the big dose q. 3 weeks due to toxicity. Perhaps brilacidin can eliminate that severe OM toxicity in q. 3 weeks cisplatin, and allow more to get the more helpful dose: those patients getting q. 3 weeks have better outcomes (lower recurrence rates):
http://www.cancernetwork.com/head-neck-cancer/three-weekly-cisplatin-superior-weekly-dose-head-and-neck-cancer
However, another study showed q. 1 week more SAEs (including more likely to get severe OM), and no difference in locoregional recurrence rates, so need more information:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564896/
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM